These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9505163)

  • 1. Effect of insulin therapy on body fat distribution in NIDDM patients with secondary sulfonylurea failure: a preliminary report.
    Takei I; Takayama S; Yamauchi A; Nakamoto S; Kitamura Y; Katsukawa F; Yamazaki H; Saruta T; Inoue S
    Eur J Clin Nutr; 1998 Feb; 52(2):153-4. PubMed ID: 9505163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes.
    Sinha A; Formica C; Tsalamandris C; Panagiotopoulos S; Hendrich E; DeLuise M; Seeman E; Jerums G
    Diabet Med; 1996 Jan; 13(1):40-6. PubMed ID: 8741811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combined treatment with insulin and sulfonylurea in non-insulin-dependent diabetic patients with secondary failure. Rationale and guidelines.
    Tiengo A; Del Prato S
    Diabetes Res Clin Pract; 1988; 4 Suppl 1():75-81. PubMed ID: 3042339
    [No Abstract]   [Full Text] [Related]  

  • 4. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
    Kabadi UM; Kabadi MU
    J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination insulin-sulfonylurea therapy.
    Lebovitz HE; Pasmantier R
    Diabetes Care; 1990 Jun; 13(6):667-75. PubMed ID: 2192850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?
    Groop L; Widén E
    Diabete Metab; 1991 May; 17(1 Pt 2):218-23. PubMed ID: 1936480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
    Johnson JL; Wolf SL; Kabadi UM
    Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin: either alone or combined with oral hypoglycemic agents.
    Firth RG
    Prim Care; 1988 Sep; 15(3):665-83. PubMed ID: 3054969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
    Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
    Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management.
    Pontiroli AE; Calderara A; Pozza G
    Diabetes Metab Rev; 1994 Apr; 10(1):31-43. PubMed ID: 7956674
    [No Abstract]   [Full Text] [Related]  

  • 11. Glutamic acid decarboxylase antibodies in non-insulin-dependent diabetes patients with secondary sulfonylurea failure in Thailand.
    Rattarasarn C; Aguilar Diosdado M; Soonthornpun S
    Diabetes Res Clin Pract; 1997 Sep; 37(3):193-7. PubMed ID: 9306041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of NIDDM with insulin agonists or substitutes.
    Galloway JA
    Diabetes Care; 1990 Dec; 13(12):1209-39. PubMed ID: 1980453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonylureas.
    Zimmerman BR
    Endocrinol Metab Clin North Am; 1997 Sep; 26(3):511-22. PubMed ID: 9314012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine.
    Riddle MC
    Horm Metab Res; 1996 Sep; 28(9):430-3. PubMed ID: 8911978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined insulin and sulfonylurea treatment in diabetes mellitus].
    Ravina A; Minuhin O
    Harefuah; 1986 Jan; 110(1):11-4. PubMed ID: 3514394
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of troglitazone on body fat distribution in type 2 diabetic patients.
    Mori Y; Murakawa Y; Okada K; Horikoshi H; Yokoyama J; Tajima N; Ikeda Y
    Diabetes Care; 1999 Jun; 22(6):908-12. PubMed ID: 10372240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of non-insulin-dependent diabetes mellitus with metformin.
    Guthrie R
    J Am Board Fam Pract; 1997; 10(3):213-21. PubMed ID: 9159660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What nurses don't know about managing NIDDM.
    Wilson BA
    Medsurg Nurs; 1994 Apr; 3(2):152-4. PubMed ID: 8173627
    [No Abstract]   [Full Text] [Related]  

  • 19. Insulin versus insulin plus sulfonylureas in type 2 diabetic patients with secondary failure to sulfonylureas.
    Scheen AJ; Lefèbvre PJ
    Diabetes Res Clin Pract; 1989 May; 6(4):S33-42; discussion S42-3. PubMed ID: 2666061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined insulin-sulfonylurea therapy in treatment of NIDDM.
    Groop LC; Groop PH; Stenman S
    Diabetes Care; 1990 Aug; 13 Suppl 3():47-52. PubMed ID: 2209344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.